Franciosi Sonia, Ryu Jae K, Choi Hyun B, Radov Lesley, Kim Seung U, McLarnon James G
Departments of Anesthesiology, University of British Columbia, Vancouver, British Columbia, Canada.
J Neurosci. 2006 Nov 8;26(45):11652-64. doi: 10.1523/JNEUROSCI.2490-06.2006.
We investigated the modulating actions of the nonselective K(+) channel blocker 4-aminopyridine (4-AP) on amyloid beta (Abeta(1-42))-induced human microglial signaling pathways and functional processes. Whole-cell patch-clamp studies showed acute application of Abeta(1-42) (5 mum) to human microglia led to rapid expression of a 4-AP-sensitive, non-inactivating outwardly rectifying K(+) current (I(K)). Intracellular application of the nonhydrolyzable analog of GTP, GTPgammaS, induced an outward K(+) current with similar properties to the Abeta(1-42)-induced I(K) including sensitivity to 4-AP (IC(50) = 5 mm). Reverse transcriptase-PCR showed a rapid expression of a delayed rectifier Kv3.1 channel in Abeta(1-42)-treated microglia. Abeta(1-42) peptide also caused a slow, progressive increase in levels of Ca(2+) (intracellular calcium) that was partially blocked by 4-AP. Chronic exposure of human microglia to Abeta(1-42) led to enhanced p38 mitogen-activated protein kinase and nuclear factor kappaB expression with factors inhibited by 4-AP. Abeta(1-42) also induced the expression and production of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha, the chemokine IL-8, and the enzyme cyclooxygenase-2; 4-AP was effective in reducing all of these pro-inflammatory mediators. Additionally, toxicity of supernatant from Abeta(1-42)-treated microglia on cultured rat hippocampal neurons was reduced if 4-AP was included with peptide. In vivo, injection of Abeta(1-42) into rat hippocampus induced neuronal damage and increased microglial activation. Daily administration of 1 mg/kg 4-AP was found to suppress microglial activation and exhibited neuroprotection. The overall results suggest that 4-AP modulation of an Abeta(1-42)-induced I(K) (candidate channel Kv3.1) and intracellular signaling pathways in human microglia could serve as a therapeutic strategy for neuroprotection in Alzheimer's disease pathology.
我们研究了非选择性钾离子通道阻滞剂4-氨基吡啶(4-AP)对淀粉样β蛋白(Aβ1-42)诱导的人小胶质细胞信号通路和功能过程的调节作用。全细胞膜片钳研究表明,将Aβ1-42(5μM)急性应用于人小胶质细胞会导致一种对4-AP敏感、非失活的外向整流钾电流(I(K))迅速表达。细胞内应用不可水解的GTP类似物GTPγS会诱导出一种与Aβ1-42诱导的I(K)性质相似的外向钾电流,包括对4-AP的敏感性(IC50 = 5 mM)。逆转录聚合酶链反应显示,在Aβ1-42处理的小胶质细胞中,延迟整流钾通道Kv3.1迅速表达。Aβ1-42肽还会导致细胞内钙([Ca2+]i)水平缓慢、逐渐升高,4-AP可部分阻断这种升高。人小胶质细胞长期暴露于Aβ1-42会导致p38丝裂原活化蛋白激酶和核因子κB表达增强,这些因子会被4-AP抑制。Aβ1-42还会诱导促炎细胞因子白细胞介素(IL)-1β、IL-6和肿瘤坏死因子-α、趋化因子IL-8以及环氧合酶-2的表达和产生;4-AP可有效降低所有这些促炎介质。此外,如果在肽中加入4-AP,Aβ1-42处理的小胶质细胞上清液对培养的大鼠海马神经元毒性会降低。在体内,将Aβ1-42注射到大鼠海马体中会诱导神经元损伤并增加小胶质细胞活化。发现每天给予1 mg/kg 4-AP可抑制小胶质细胞活化并表现出神经保护作用。总体结果表明,4-AP对人小胶质细胞中Aβ1-42诱导的I(K)(候选通道Kv3.1)和细胞内信号通路的调节可作为阿尔茨海默病病理学中神经保护的治疗策略。